NMN Treatment Restores Angiogenic Processes in Aged Cerebromicrovascular Endothelial Cells

The Study

Researchers at the Vascular Cognitive Impairment and Neurodegeneration Program, led by Kiss, have made significant strides in understanding the impact of aging on cerebromicrovascular health. Their recent study, published in GeroScience, explores the effects of nicotinamide mononucleotide (NMN) on age-related impairment of angiogenesis in cerebromicrovascular endothelial cells. Using a combination of wound-healing assays and electric cell-substrate impedance sensing (ECIS) technology, the team investigated the role of NMN in restoring endothelial cell function.

What They Measured and What They Found

The study found that aged cerebromicrovascular endothelial cells exhibit impaired proliferation, cellular migration, and ability to form capillary-like structures, compared to young cells. NMN treatment significantly improved these angiogenic processes and attenuated H2O2 production, with notable increases in cellular migration and capillary-like structure formation. The team also observed that pre-treatment with EX-527, a pharmacological inhibitor of SIRT1, prevented NMN-mediated restoration of angiogenic processes.

The Mechanism: Why It Works

The study suggests that normal cellular NAD+ levels are essential for normal endothelial angiogenic processes. Age-related cellular NAD+ depletion and consequential SIRT1 dysregulation may be a potentially reversible mechanism underlying impaired angiogenesis and cerebromicrovascular rarefaction in aging. The team's findings imply that NMN, as a key NAD+ intermediate, plays a critical role in restoring angiogenic processes in aged cerebromicrovascular endothelial cells.

Practical Application Protocol

Based on the study's data, a potential protocol for healthy adults seeking to optimize cerebromicrovascular health could involve supplementing with NMN. While the study does not provide direct dosage information, extrapolating from the methodology, a potential dosage could be in the range of 250-500 mg per day. It is essential to note that individual results may vary, and more research is needed to determine the optimal dosage and duration of NMN supplementation. A sample protocol could include:

• Supplementing with NMN (250-500 mg per day) for 6-12 weeks


• Combining NMN with other NAD+ precursors, such as nicotinamide riboside (NR), to potentiate the effect


• Monitoring progress through regular blood flow and cognitive function assessments

Study Limitations

The study has several limitations, including the use of cerebromicrovascular endothelial cells isolated from F344xBN rats, which may not directly translate to human populations. Additionally, the study's sample size is not explicitly stated, and the duration of NMN treatment is not specified. Further research is needed to fully understand the effects of NMN on human cerebromicrovascular health.

Disclaimer: This article is for informational and educational purposes only. The information presented does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before modifying your diet, supplementation, or exercise routines. The scientific studies cited reflect the state of knowledge at their publication date and may be subject to revision.